1. Home
  2. APRE vs BNKK Comparison

APRE vs BNKK Comparison

Compare APRE & BNKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.73

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

BNKK

Bonk Inc.

N/A

Current Price

$1.40

Market Cap

11.9M

ML Signal

N/A

Company Overview

Basic Information
Metric
APRE
BNKK
Founded
2006
2018
Country
United States
United States
Employees
N/A
10
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
11.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
APRE
BNKK
Price
$0.73
$1.40
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
125.6K
420.8K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.11
52 Week High
$2.22
$7.19

Technical Indicators

Market Signals
Indicator
APRE
BNKK
Relative Strength Index (RSI) 38.93 32.01
Support Level $0.57 $0.12
Resistance Level $0.81 $2.90
Average True Range (ATR) 0.06 0.18
MACD -0.02 -0.02
Stochastic Oscillator 15.05 13.33

Price Performance

Historical Comparison
APRE
BNKK

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About BNKK Bonk Inc.

Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.

Share on Social Networks: